Immunic Inc (NASDAQ:IMUX) announced that it will present data from its Phase 2 CALLIPER and CALVID-1 clinical trials of its lead asset vidofludimus calcium.
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024 lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Two leading multiple sclerosis (MS) experts Nancy Sicotte, MD, director of Multiple Sclerosis and Neuroimmunology at Cedars-Sinai, and Pascal Sati, PhD, direc
The Latest About Multiple Sclerosis newswise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newswise.com Daily Mail and Mail on Sunday newspapers.
Daniel Ontaneda, MD, PhD, Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 chair, discussed what attendees can expect at this year's meeting, as well as how the theme of "Breaking Barriers in MS" will be implemented.